Health-Related Quality of Life During Treatment for Renal Cell Carcinoma: Results from a Phase II Study of Axitinib - Abstract
Global Outcomes Research, Pfizer Inc., New London, CT 06320, USA.
Content on UroToday and UroToday International Journal is copyrighted and can be used for personal, noncommercial use only. You can order presentation-ready copies for distribution to your colleagues, clients or customers by emailing UroToday at commercialreprints@urotoday.com. Request a reprint quote of this article now, please include the title of the article and number or copies requested.
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810 UroToday International Journal Correspondence
Privacy Policy | © 2010 Digital Science Press, Inc ® All Rights Reserved |





